Cambridge Isotope Laboratories and Nexomics Biosciences Sign an Exclusive Worldwide Commercial Supply Agreement
January 31, 2014Cambridge Isotope Laboratories, Inc. and Nexomics Biosciences sign an exclusive worldwide commercial supply agreement
BOSTON - Cambridge Isotope Laboratories, Inc. (CIL), the world’s leading supplier of stable isotopes and stable isotope-enriched small molecules, is working together with Nexomics Biosciences, a structural biology and protein-production contract research organization, to provide isotope-labeled proteins to life science research organizations.
Scientific research, guided by stable isotope-enriched protein reagents, has become commonplace in academic and biopharmaceutical research. CIL and Nexomics will address this demand by producing and offering catalog and custom isotope-enriched proteins.
Under the terms of the agreement, Nexomics will provide protein-production services, while CIL will provide global sales and marketing support. "We are very excited to enter into agreement with CIL, one of the most respected names in the field of stable isotope reagents for biomedical research. These reagents have a wide range of applications. In addition to producing catalog proteins, our extensive experience in producing isotope-enriched proteins will be invaluable to our clients," says Gaetano Montelione, CEO of Nexomics Biosciences.
"Nexomics' success in developing techniques to determine protein structure using nuclear magnetic resonance (NMR) spectroscopy nicely complements CIL's mission to offer isotope-enriched reagents used to produce labeled recombinant protein. The capabilities that Nexomics offers, such as the production and NMR analysis of isotope-enriched protein, will enhance and expand CIL's current product offering," says Joel Bradley, CEO of Cambridge Isotope Laboratories.
About Cambridge Isotope Laboratories
Cambridge Isotope Laboratories, Inc. (www.isotope com) is the world's premier supplier of stable isotopes and stable isotope-labeled compounds for research applications in structural biology, proteomics, genomics, molecular biology, metabolic research, clinical and diagnostic research and ultra-trace environmental analysis. With laboratory facilities located in four countries - the United States, Canada, Germany and France - CIL is able to specialize in the process of labeling biochemical and organic compounds with highly enriched stable (nonradioactive) isotopes of carbon, hydrogen, nitrogen and oxygen. For more information on CIL, visit http://www.isotope.com.
About Nexomics Biosciences, Inc.
Nexomics Biosciences is a contract research organization (CRO), offering a broad array of gene-to-structure services to the biopharmaceutical community. By utilizing a fully integrated protein structure production pipeline, Nexomics can offer a variety of services from bioinformatics, target profiling, gene cloning, recombinant protein expression, laboratory-scale fermentation, crystallization, NMR structural studies, X-ray crystallographic structural studies, target validation and functional annotation. For more information about Nexomics Biosciences, visit http://www.nexomics.com.
Contacts:
Christine Krisko | Marketing Communications Manager
978-296-1930 | ckrisko@isotope.com
